Aquestive Therapeutics is trading 5.54% lower at $3.83, with no clear company-specific news explaining the decline. - The biotech ETF XBI is down 2.06%, while the Nasdaq Composite is down 1.84%; these pressures may be contributing, but evidence does not establish a direct cause. - The FDA’s acceptance of the Anaphylm NDA resubmission and March 16, 2027 review date were announced October 15; available reporting does not link them to the drop.